Preparation and Evaluation of Niosomal Formulation for Solubility Enhancement of Anti-fungal Agent for the Treatment of Oral Candidiasis

The human fungal pathogen Candida albicans is notorious for causing oral infectious diseases, notably oral thrush, particularly in immunocompromised individuals with conditions such as hyposalivation, diabetes mellitus, and prolonged use of antibiotics or immunosuppressive medications, often compounded by poor oral hygiene practices. Addressing such infections often involves anti-fungal medications, with Clotrimazole being a prominent choice. However, Clotrimazole, classified as a BCS class II drug, poses challenges due to its high permeability coupled with low solubility in water.

Traditionally available in lozenge form, Clotrimazole's efficacy is hindered by its uneven distribution within saliva, necessitating frequent dosing and potentially compromising patient compliance. To overcome these limitations, this study proposes a novel approach: a niosomal-based subgingival film formulation of Clotrimazole. By leveraging the advantages of niosomes, including enhanced drug solubilization capacity and prolonged release kinetics, this formulation aims to improve drug efficacy while simultaneously enhancing patient compliance by reducing dosing frequency.

Initial findings from the study are promising. The prepared niosomal film demonstrates favorable characteristics, including high entrapment efficiency and potent anti-fungal activity. Moreover, the release profile of the drug from the niosomal film exhibits superior performance compared to conventional drug-loaded films. These results suggest that the niosomal-based formulation holds significant potential for enhancing the therapeutic outcomes of Clotrimazole in the treatment of oral fungal infections.

By addressing the limitations of conventional Clotrimazole formulations through innovative niosomal technology, this study offers a promising avenue for improving the management of oral fungal infections. Further research and clinical trials are warranted to validate these findings and pave the way for the development of effective, patient-friendly treatments in this important area of healthcare.